Paula Green Sells 1,194 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 1,194 shares of Twist Bioscience stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $46.58, for a total transaction of $55,616.52. Following the completion of the sale, the senior vice president owned 165,445 shares of the company’s stock, valued at approximately $7,706,428.10. The trade was a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Paula Green also recently made the following trade(s):

• On Monday, December 22nd, Paula Green sold 273 shares of Twist Bioscience stock. The stock was sold at an average price of $34.56, for a total transaction of $9,434.88.

Twist Bioscience Price Performance

NASDAQ:TWST traded down $1.02 during mid-day trading on Thursday, reaching $47.10. The stock had a trading volume of 2,162,437 shares, compared to its average volume of 1,485,586. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $54.74. The stock has a market capitalization of $2.89 billion, a PE ratio of -36.80 and a beta of 2.24. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.33. The stock has a 50-day simple moving average of $36.23 and a two-hundred day simple moving average of $31.84.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The business had revenue of $103.70 million during the quarter, compared to the consensus estimate of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The company’s revenue was up 16.9% compared to the same quarter last year. On average, equities analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently made changes to their positions in TWST. Quarry LP bought a new stake in shares of Twist Bioscience in the 3rd quarter worth $28,000. Smartleaf Asset Management LLC boosted its holdings in Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after purchasing an additional 442 shares during the last quarter. SBI Securities Co. Ltd. grew its position in Twist Bioscience by 68.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after purchasing an additional 571 shares in the last quarter. National Bank of Canada FI purchased a new stake in Twist Bioscience in the 3rd quarter valued at about $46,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Twist Bioscience by 15.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock worth $85,000 after buying an additional 302 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Stephens started coverage on Twist Bioscience in a research report on Monday, November 3rd. They set an “overweight” rating and a $41.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Evercore ISI boosted their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Barclays lifted their target price on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday. Seven analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $45.88.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.